Male sex hormones interfere with the body’s ability to fight bladder cancer, likely explaining why males experience higher cancer rates and more deadly disease, according to a new study.
These findings, published in Science Immunology, could represent a significant step toward unraveling why disparities in cancer incidence, prognosis and treatment response exist between males and females. Males are more likely than females to develop most types of cancer. This is most evidently displayed in bladder cancer rates; studies show males are three to five times more likely than females to develop it.
“Historically, it was thought males may have higher cancer rates because they are more likely to engage in behaviors that predispose them to cancer, such as smoking,” said a senior and corresponding author of the study and research scientist at Cedars-Sinai. “We observed that biology of sex, not just behavior, is an important factor in cancer development.”
Androgens, sex hormones produced in higher amounts in males, promote the development of the reproductive system. A team of investigators discovered that androgens interfere with the adaptive immune system, which comprises cells that remember how to respond to pathogens with which the body has previously come into contact. Androgens seem to block the activity of tumor-killing cells called CD8+ T cells, the investigators report.
The authors studied a mouse bladder cancer model in which more aggressive tumors arise in male mice, mimicking the incidence observed in humans. With this model, they experimented with removing various immune cells in mice of both sexes. When they removed CD8+ T cells, the male and female differences in cancer severity disappeared. This suggested that the way androgens interact with CD8+ T cells contributes to the sex differences in bladder cancer. Furthermore, the team found tumors grew more aggressively in mice with higher levels of androgens.
The most surprising finding, however, was observed when the team performed genetic sequencing of CD8+ T cells from the tumors, the author said. The CD8+ T cells in males showed more signs of exhaustion and dysfunction due to androgen activity. Androgen deprivation therapy, a common clinical treatment for prostate cancer, was effective in reducing bladder tumor size in male mice and improved the efficacy of immunotherapy.
The findings may explain in part why male and female patients respond differently to a type of cancer therapy called an immunotherapy, which helps the body’s CD8+ T cells attack cancer cells.
“T cells are like soldiers commissioned to kill tumor cells. However, they can become exhausted, so immunotherapy is used to rejuvenate them,” the author said. “Unfortunately, many cancer patients do not respond to immunotherapy. These findings suggest male patients may benefit more from immunotherapy when combined with androgen deprivation therapy.”
The researchers plan to continue studying how and when androgen-inhibiting therapy may aid bladder cancer treatment. Similar to other cancers like breast cancer and prostate cancer that are affected by sex hormones, hormone therapy for bladder cancer may work best when given early in the course of the disease.
https://www.science.org/doi/10.1126/sciimmunol.abq2630
Hormones contribute to sex disparities in bladder cancer
- 1,279 views
- Added
Latest News
Circadian rhythms can influ…
By newseditor
Posted 27 Apr
With hybrid brains, these m…
By newseditor
Posted 27 Apr
Blocking activation of NF-κ…
By newseditor
Posted 27 Apr
Vitamin D regulates microbi…
By newseditor
Posted 27 Apr
Role of alternative splicin…
By newseditor
Posted 27 Apr
Other Top Stories
Obese mice lose a third of their fat using a natural protein
Read more
Gut hormone secretin and brown fat interact to tell the brain it's…
Read more
Antidiabetic effect of drug metformin linked to iron homeostasis
Read more
Ghrelin promotes conditioning to food-related odors
Read more
Receptor for exercise hormone irisin found!
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Single dose creatine improv…
By newseditor
Posted 27 Apr
Autonomous circadian rhythm…
By newseditor
Posted 27 Apr
Functional sensory circuits…
By newseditor
Posted 27 Apr
Positive selection CRISPR s…
By newseditor
Posted 27 Apr
Focal clusters of peri-syna…
By newseditor
Posted 27 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar